Tuesday, December 10, 2024

2024 Top Story in Cardiology: The ESPRIT Trial

 Here is the link.

 https://www.practiceupdate.com/c/173221/2/2/?elsca1=emc_enews_daily-digest&elsca2=email&elsca3=practiceupdate_cardio&elsca4=cardiology&elsca5=newsletter&rid=MzEwODYyNjA4MjA0S0&lid=20845073

 Here is an excerpt.

 Hypertension remains a common and undertreated cardiovascular risk factor throughout the world. The recommended target for the treatment of high blood pressure (BP) has long been a systolic BP of less than 140 mm Hg. The SPRINT trial1 did show that targeting a systolic BP of less than 120 mm Hg was better than 140 mm Hg in patients at high cardiovascular risk but without diabetes or stroke. The ESPRIT trial2 has now validated and extended the SPRINT findings to include patients with diabetes or stroke.

No comments: